Libido · Melanocortin receptor agonist
PT-141 (Bremelanotide)
- Drug class
- Melanocortin receptor agonist
- Status
- FDA-approved · HSDD
- Also known as
- Bremelanotide, Vyleesi
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What PT-141 (Bremelanotide) is studied for
- Hypoactive sexual desire disorder in premenopausal women (FDA-approved)
- Sexual arousal and desire research in men and women
- Erectile dysfunction (off-label, limited evidence)
Mechanism of action
Non-selective agonist of melanocortin receptors (primarily MC4R) in the hypothalamus. Activates the central sexual desire circuit upstream of dopamine release — independent of vascular pathways.
Frequently asked questions
How is PT-141 / Vyleesi used?
Subcutaneous injection (autoinjector for Vyleesi) 45 minutes before anticipated sexual activity. No more than once per 24 hours and no more than 8 doses per month.
What are the side effects?
Nausea (most common, ~40%), flushing, headache, and transient blood-pressure increase (~6 mmHg). Hyperpigmentation has been reported with frequent use.
Who should not use it?
Uncontrolled hypertension or known cardiovascular disease — the transient BP rise is the main safety concern. A clinician should review every case.
Does it work for men?
PT-141 has shown effects on erectile function and desire in male trials but is not FDA-approved for men. Off-label use exists; evidence is preliminary.
Build the PT-141 (Bremelanotide) protocol stack
Research protocols commonly pair PT-141 (Bremelanotide) with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Libido
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Libido after menopauseJournal
- Kisspeptin-10Peptide
- Testosterone for womenMedication